Buy Acadia

Logo for stock ACAD (Acadia)

Amount

£
GBP

Latest price

$23.52
(£1.00 = $1.328)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$3.938B

P/E ratio

17.11

EPS

$1.375

Beta

0.75

Dividend rate

N/A

Dividend yield

N/A

About

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

CEO

Ms. Catherine Owen Adams

Employees

653

Sector

Health

Company HQ

SAN DIEGO, United States of America

Website

News

Logo for news article #0 (GMAB vs. ACAD: Which Stock Is the Better Value Option?)

GMAB vs. ACAD: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research

August 01, 2025

Logo for news article #1 (Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?)

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

July 30, 2025

Logo for news article #2 (Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In)

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

ACADIA's valuation is justified by strong revenue growth from NUPLAZID and DAYBUE, with total 2025 revenue guidance of $1B–$1.1B. ACP-101's phase 3 trial for Prader-Willi syndrome is a high-risk catalyst, with a 60–65% probability of success due to improved trial design. We believe ACP-101's market potential is lower than consensus, estimating $400M peak revenue due to late market entry and dosing frequency.

Seeking Alpha

July 28, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.